What is a developability assessment and when do you need it?
A developability assessment is the early reality check on whether your candidate can be made into a real, stable, manufacturable drug, not just whether it works in an assay. It sits at the front of the CMC stage, before you sink real money into cell line and process development. The job is to flag the liabilities that quietly sink programs later: a molecule that aggregates at the concentration a subcutaneous dose needs, an antibody sequence carrying oxidation or deamidation hot spots, a small molecule with a polymorph problem or solubility so poor that no formulation will rescue it. You want those answers while a candidate is still cheap to drop or re-engineer, not after a GMP campaign.
The right time to run one is at candidate selection or lead nomination, when you have one to a handful of molecules and have to pick. For biologics, that often means screening a panel of antibody or protein candidates head to head on expression titer, aggregation, viscosity, thermal and colloidal stability, and forced-degradation behavior, then ranking them so the molecule you advance is the one chemistry and manufacturing can actually live with. For small molecules, it leans toward solid-form and salt screening, crystallinity, hygroscopicity, solubility and permeability, and early stability under stress. Either way, the deliverable is a ranked, evidence-backed read on which candidate carries the least CMC risk.
Skipping this step is one of the more expensive mistakes in early development. A developability liability caught at nomination costs a few studies and maybe a back-up molecule. The same liability caught during process development or, worse, after a clinical batch fails its stability program, costs months and a re-engineering effort that can reset the whole CMC timeline. The assessment is not regulatory work and most of it runs non-GMP, but it shapes the formulation strategy, the target product profile, and the manufacturability assumptions that everything downstream inherits.
What does a developability assessment CDMO actually do?
The specific battery depends entirely on your modality, which is why matching the CDMO to your molecule type matters more than the size of the logo. The work splits into a few recognizable blocks, and a good vendor scopes them against your target product profile rather than running a fixed menu.
For antibodies and proteins, the core of the work is biophysical and in silico characterization run across a candidate panel. For small molecules and peptides, the center of gravity moves to solid-state and physicochemical properties. Across modalities, the output is a comparative scorecard plus a written recommendation on which candidate to advance and which liabilities to engineer out or design around.
- Biologics liability screening: high-throughput expression and titer, monomer purity and aggregation (SEC, DLS), thermal and colloidal stability (Tm, Tagg, DSF, DSC), viscosity at high concentration for subcutaneous feasibility, and charge variant profiling.
- Sequence and in silico assessment: identifying and scoring chemical liability motifs (deamidation, isomerization, oxidation, free cysteines, N-glycosylation, aggregation-prone regions) and predicting immunogenicity risk before you commit to a lead.
- Forced degradation and stress studies: exposing candidates to heat, low and high pH, light, agitation, and freeze-thaw to surface degradation pathways and rank relative stability early.
- Small-molecule solid-form work: salt and polymorph screening, crystallinity, hygroscopicity, solubility across pH, and permeability, plus early stress stability to flag solid-state and degradation risks.
- Manufacturability and formulation read: a view on whether the candidate can be expressed or synthesized at scale, formulated at the required dose and route, and held stable long enough to be a viable product.
- A ranked recommendation: a comparative developability scorecard across the candidate panel with a clear, evidence-backed call on which molecule carries the least CMC risk and where the residual liabilities sit.
How do you choose a developability assessment CDMO?
Start with modality fit, then work through quality, capacity, region, and how the vendor handles your data and your molecule. The checklist below is what separates a useful, decision-grade assessment from a generic panel of numbers you cannot act on. Score two or three candidates against the same written scope so you are comparing like for like, and ask to see an example scorecard and recommendation from a comparable program before you sign.
- Modality and indication fit: confirm the CDMO runs developability work on your molecule type routinely (mAb, bispecific, fusion protein, ADC, peptide, oligonucleotide, or small molecule). The assay battery for an antibody panel and a small-molecule solid-form screen share almost nothing, and a vendor stretching outside its lane will give you a thinner read.
- Quality and GxP status: most developability work is non-GMP and that is appropriate, but check the vendor's broader quality posture: qualified assays, documented methods, sound data integrity, and the ability to carry the same molecule cleanly into GMP development later so you are not forced into a method transfer.
- Capacity and lead time: developability sits on the critical path because nomination cannot finalize until the results are in. Confirm a realistic slot, turnaround on the report and not just the bench work, and whether the panel can run across all your candidates in parallel rather than serially.
- Region and regulatory track record: consider where the work runs and whether the vendor has supported programs that went on to file. A CDMO that has carried molecules from developability through IND understands which early signals a reviewer and a process team will care about later.
- Data quality and deliverable: insist the output is a comparative, ranked recommendation with the underlying data, not a raw data dump. Ask what the assay acceptance criteria are and how borderline candidates are handled, since the entire point is a defensible go/no-go call.
- IP and confidentiality: you are sharing sequences, structures, or lead compounds before anything is protected. Confirm the CDA terms, who owns any data and analysis generated, and how your molecule and results are handled, especially when the vendor also offers downstream manufacturing it might want to win.